RSV Vaccine in Transplant Recipients

Phase 3

Not yet recruiting

• Conditions: Vaccine Response Impaired; Respiratory Syncytial Virus Infections; Immune Suppression

• Registration Number: NCT06593210
• Lead Sponsor: University Health Network, Toronto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-9-9
• Last Update Posted: 23 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Inclusion Criteria:<br><br> - Stable outpatient lung and allogeneic HCT recipients more than 6 months<br> post-transplantation<br><br>Exclusion Criteria:<br><br> - Currently pregnant or planning to conceive or breastfeeding<br><br> - IVIg in last 30 days<br><br> - Previous rituximab in last 6 months<br><br> - Active CMV infection<br><br> - Diagnosis of RSV in the past 90 days

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Humoral immunogenicity

Secondary Outcome Measures

Name	Time	Method
Cellular immunogenicity;Safety of the vaccine;Long-term safety